UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic

Journal of experimental & clinical cancer research, 2016-11, Vol.35 (1), p.179-179, Article 179

2016

Volltextzugriff (PDF)

The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy

International journal of molecular sciences, 2017-06, Vol.18 (7), p.1374

2017

Volltextzugriff (PDF)

The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer

Molecular cancer, 2018-02, Vol.17 (1), p.46-46, Article 46

2018

Volltextzugriff (PDF)

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment

Journal of experimental & clinical cancer research, 2019-02, Vol.38 (1), p.91-9, Article 91

2019

Volltextzugriff (PDF)

Mono(ADP-ribosyl)ation Enzymes and NAD + Metabolism: A Focus on Diseases and Therapeutic Perspectives

Cells (Basel, Switzerland), 2021-01, Vol.10 (1), p.128

2021

Volltextzugriff (PDF)

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

Journal of experimental & clinical cancer research, 2019-02, Vol.38 (1), p.90-90, Article 90

2019

Volltextzugriff (PDF)

A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options

Exploration of targeted anti-tumor therapy, 2022-10, Vol.3 (5), p.570-581

2022

Volltextzugriff (PDF)

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma

Journal of experimental & clinical cancer research, 2022-08, Vol.41 (1), p.1-245, Article 245

2022

Volltextzugriff (PDF)

Retraction Note: Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors

BMC cancer, 2021-01, Vol.21 (1), p.100-100, Article 100

2021

Volltextzugriff (PDF)

FKBP51 Immunohistochemical Expression: A New Prognostic Biomarker for OSCC?

International journal of molecular sciences, 2017-02, Vol.18 (2), p.443-443

2017

Volltextzugriff (PDF)

FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC

Oncotarget, 2015-05, Vol.6 (14), p.12697-12709

2015

Volltextzugriff (PDF)

Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage

PloS one, 2012-05, Vol.7 (5), p.e36177

2012

Volltextzugriff (PDF)

Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress

Cancers, 2021-07, Vol.13 (15), p.3822

2021

Volltextzugriff (PDF)

CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCC

Cancers, 2019-10, Vol.11 (10), p.1582

2019

Volltextzugriff (PDF)

The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis

Heliyon, 2021-11, Vol.7 (11), p.e08399-e08399, Article e08399

2021

Volltextzugriff (PDF)

Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity

PloS one, 2012-11, Vol.7 (11), p.e49298-e49298

2012

Volltextzugriff (PDF)

CCDC6: the identity of a protein known to be partner in fusion

International journal of cancer, 2018-04, Vol.142 (7), p.1300-1308

2018

Volltextzugriff (PDF)

Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness

Clinical cancer research, 2005-11, Vol.11 (22), p.8019-8027

2005

Volltextzugriff (PDF)

Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer

Cancer letters, 2022-04, Vol.532, p.215581-215581, Article 215581

2022

Volltextzugriff (PDF)

USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs

Lung cancer (Amsterdam, Netherlands), 2017-05, Vol.107, p.41-49

2017

Volltextzugriff (PDF)

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells

Oncotarget, 2017-05, Vol.8 (19), p.31815-31829

2017

Volltextzugriff (PDF)

Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET PTC-transformed thyroid cells

Oncogene, 2004-03, Vol.23 (12), p.2188-2196

2004

Volltextzugriff (PDF)

Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma

Lung cancer (Amsterdam, Netherlands), 2019-09, Vol.135, p.56-65

2019

Volltextzugriff (PDF)

NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells

Cancers, 2019-12, Vol.12 (1), p.44

2019

Volltextzugriff (PDF)

Detection of CAF-1/p60 in peripheral blood as a potential biomarker of HNSCC tumors

Oral oncology, 2021-09, Vol.120, p.105367-105367, Article 105367

2021

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(49)

Publikationsform

Sprache

Englisch
(51)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic

The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy

The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment

Mono(ADP-ribosyl)ation Enzymes and NAD + Metabolism: A Focus on Diseases and Therapeutic Perspectives

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma

Retraction Note: Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors

FKBP51 Immunohistochemical Expression: A New Prognostic Biomarker for OSCC?

FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC

Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage

Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress

CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCC

The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis

Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity

CCDC6: the identity of a protein known to be partner in fusion

Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness

Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer

USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells

Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET PTC-transformed thyroid cells

Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma

NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells

Detection of CAF-1/p60 in peripheral blood as a potential biomarker of HNSCC tumors

Suchergebnisse filtern